HRP20220456T1 - Dihidropirimidinoizohinolinoni i njihove farmaceutske kompozicije za liječenje multiple skleroze - Google Patents
Dihidropirimidinoizohinolinoni i njihove farmaceutske kompozicije za liječenje multiple skleroze Download PDFInfo
- Publication number
- HRP20220456T1 HRP20220456T1 HRP20220456TT HRP20220456T HRP20220456T1 HR P20220456 T1 HRP20220456 T1 HR P20220456T1 HR P20220456T T HRP20220456T T HR P20220456TT HR P20220456 T HRP20220456 T HR P20220456T HR P20220456 T1 HRP20220456 T1 HR P20220456T1
- Authority
- HR
- Croatia
- Prior art keywords
- ylmethoxy
- dihydro
- pyrimido
- isoquinolin
- dioxan
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- -1 Methylamide 5-[2-([1,4]Dioxan-2-ylmethoxy)-4-oxo-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-9-yl]- pyridine-2-carboxylic acids Chemical class 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 claims 1
- RFTGHRMNRSHWBL-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=CC=C3CCN2C(=O)N=C1OCC1COCCO1 RFTGHRMNRSHWBL-UHFFFAOYSA-N 0.000 claims 1
- FUKDWBZBOLZEPO-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1,3-oxazol-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC=4OC=CN=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 FUKDWBZBOLZEPO-UHFFFAOYSA-N 0.000 claims 1
- JRFGYWSBNKDLGZ-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1-ethylpyrazol-4-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NN(CC)C=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 JRFGYWSBNKDLGZ-UHFFFAOYSA-N 0.000 claims 1
- UFXFBYILWDOVNC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1-methylindol-5-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C2N(C)C=CC2=CC=1C(C=1)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 UFXFBYILWDOVNC-UHFFFAOYSA-N 0.000 claims 1
- JUURNCDFTFERJD-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1-propylpyrazol-4-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NN(CCC)C=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 JUURNCDFTFERJD-UHFFFAOYSA-N 0.000 claims 1
- GHTUWHMYNSQWBE-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1h-indazol-5-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=C5C=NNC5=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 GHTUWHMYNSQWBE-UHFFFAOYSA-N 0.000 claims 1
- LXEDZWSAQCWVOW-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1h-indol-2-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4NC5=CC=CC=C5C=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 LXEDZWSAQCWVOW-UHFFFAOYSA-N 0.000 claims 1
- NFUONRNKWZXWKG-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1h-indol-5-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=C5C=CNC5=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 NFUONRNKWZXWKG-UHFFFAOYSA-N 0.000 claims 1
- UBAOKCMYALUHJA-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(1h-pyrazol-4-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C4=CNN=C4)C=C3CCN2C(=O)N=C1OCC1COCCO1 UBAOKCMYALUHJA-UHFFFAOYSA-N 0.000 claims 1
- IOEBVXSFJUYZAS-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-ethoxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CCOC1=NC=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 IOEBVXSFJUYZAS-UHFFFAOYSA-N 0.000 claims 1
- IIOUXJJBJJESOH-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-methoxyphenyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 IIOUXJJBJJESOH-UHFFFAOYSA-N 0.000 claims 1
- FOLJWRCFTUIJDT-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-methoxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=NC=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 FOLJWRCFTUIJDT-UHFFFAOYSA-N 0.000 claims 1
- VBOGBNPLAJEBNR-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyrazin-2-ylethyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(CCC=4N=CC=NC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 VBOGBNPLAJEBNR-UHFFFAOYSA-N 0.000 claims 1
- CMMVXNAUFZNASV-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyridin-2-ylethyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(CCC=4N=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 CMMVXNAUFZNASV-UHFFFAOYSA-N 0.000 claims 1
- OJUGVILFVLNQIN-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyridin-2-ylethynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC=4N=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 OJUGVILFVLNQIN-UHFFFAOYSA-N 0.000 claims 1
- HPNCYWFFYIFFCB-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyridin-3-ylethynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC=4C=NC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 HPNCYWFFYIFFCB-UHFFFAOYSA-N 0.000 claims 1
- JWIVRAVRGYCFQU-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyridin-4-ylethynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC=4C=CN=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 JWIVRAVRGYCFQU-UHFFFAOYSA-N 0.000 claims 1
- RORQQZAQQRNVCC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyrimidin-2-ylethynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC=4N=CC=CN=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 RORQQZAQQRNVCC-UHFFFAOYSA-N 0.000 claims 1
- UHBVJNATYAFKGG-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(2-pyrrolidin-1-ylpyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C(=NC=CC=4)N4CCCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 UHBVJNATYAFKGG-UHFFFAOYSA-N 0.000 claims 1
- OEPJEARHYWJBCU-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-ethyl-3-hydroxypent-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(O)(CC)CC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 OEPJEARHYWJBCU-UHFFFAOYSA-N 0.000 claims 1
- DJLCKRYRNSUXLI-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-3-methylbut-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(C)(O)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 DJLCKRYRNSUXLI-UHFFFAOYSA-N 0.000 claims 1
- YLALDPZXHDFNQM-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-3-phenylbut-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=CC=CC=1C(O)(C)C#CC(C=1)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 YLALDPZXHDFNQM-UHFFFAOYSA-N 0.000 claims 1
- QOACGHRYBVFGBR-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-3-pyridin-3-ylprop-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=CN=CC=1C(O)C#CC(C=1)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 QOACGHRYBVFGBR-UHFFFAOYSA-N 0.000 claims 1
- DKAOVRWVJAWHND-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-3-pyridin-3-ylpropyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=CN=CC=1C(O)CCC(C=1)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 DKAOVRWVJAWHND-UHFFFAOYSA-N 0.000 claims 1
- FQYOAZIPVGMPMX-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-4-methylpent-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(O)C(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 FQYOAZIPVGMPMX-UHFFFAOYSA-N 0.000 claims 1
- XYEJBVUGGUZHMQ-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxy-5-methylhex-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(O)CC(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 XYEJBVUGGUZHMQ-UHFFFAOYSA-N 0.000 claims 1
- VUIPUKDNNNJULW-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxyhex-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(O)CCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 VUIPUKDNNNJULW-UHFFFAOYSA-N 0.000 claims 1
- ZGJBNCCPCLGHNI-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-hydroxyprop-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCO)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 ZGJBNCCPCLGHNI-UHFFFAOYSA-N 0.000 claims 1
- LQTVLMJGKMGMCX-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-imidazol-1-ylprop-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CCN4C=NC=C4)C=C3CCN2C(=O)N=C1OCC1COCCO1 LQTVLMJGKMGMCX-UHFFFAOYSA-N 0.000 claims 1
- AOYPYDSFTKKNAR-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-methoxyphenyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 AOYPYDSFTKKNAR-UHFFFAOYSA-N 0.000 claims 1
- HLAQLEHDEDDXKD-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(3-methoxyprop-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 HLAQLEHDEDDXKD-UHFFFAOYSA-N 0.000 claims 1
- GITIKJVOXNTBIV-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(4-hydroxybut-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCCO)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 GITIKJVOXNTBIV-UHFFFAOYSA-N 0.000 claims 1
- KDECCZNQCUZKMM-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(4-methoxyphenyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 KDECCZNQCUZKMM-UHFFFAOYSA-N 0.000 claims 1
- QKGNRHGIXBMVIU-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(4-morpholin-4-ylphenyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=CC(=CC=4)N4CCOCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 QKGNRHGIXBMVIU-UHFFFAOYSA-N 0.000 claims 1
- MBCWUPQNTZIPCF-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(5-methoxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CN=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 MBCWUPQNTZIPCF-UHFFFAOYSA-N 0.000 claims 1
- JFJQSOXFJBIMOJ-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(5-methylfuran-2-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(C)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 JFJQSOXFJBIMOJ-UHFFFAOYSA-N 0.000 claims 1
- AXUGDRKDFNZHBY-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-ethoxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NC(OCC)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 AXUGDRKDFNZHBY-UHFFFAOYSA-N 0.000 claims 1
- YDYBKRUWQDWECH-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-methoxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NC(OC)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 YDYBKRUWQDWECH-UHFFFAOYSA-N 0.000 claims 1
- FKDTXJMMDQIQOI-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-methylpyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NC(C)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 FKDTXJMMDQIQOI-UHFFFAOYSA-N 0.000 claims 1
- KWHDRSJRWXRARR-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-morpholin-4-ylpyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=NC(=CC=4)N4CCOCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 KWHDRSJRWXRARR-UHFFFAOYSA-N 0.000 claims 1
- WDXDBZNLHDATCD-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-propan-2-yloxypyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NC(OC(C)C)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 WDXDBZNLHDATCD-UHFFFAOYSA-N 0.000 claims 1
- RTDPLTPARBVFOC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(6-pyrrolidin-1-ylpyridin-3-yl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=NC(=CC=4)N4CCCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 RTDPLTPARBVFOC-UHFFFAOYSA-N 0.000 claims 1
- KEYIADWBIYGSQO-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(furan-2-ylmethylamino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(NCC=4OC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 KEYIADWBIYGSQO-UHFFFAOYSA-N 0.000 claims 1
- KSGKMLVYIUJQMZ-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC=4N=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 KSGKMLVYIUJQMZ-UHFFFAOYSA-N 0.000 claims 1
- HYVQFMCVFHCARC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(1-methylpyrazol-3-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C=CC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 HYVQFMCVFHCARC-UHFFFAOYSA-N 0.000 claims 1
- BSSVGTOJDBSHHZ-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CC1=NOC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 BSSVGTOJDBSHHZ-UHFFFAOYSA-N 0.000 claims 1
- LJIYHSOKPSIAOS-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(3-methyl-1,2-oxazol-5-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1N=C(C)C=C1COC1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 LJIYHSOKPSIAOS-UHFFFAOYSA-N 0.000 claims 1
- XKTDLLOBRXQBKU-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(5-ethyl-1,2,4-oxadiazol-3-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(CC)=NC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 XKTDLLOBRXQBKU-UHFFFAOYSA-N 0.000 claims 1
- MZEXYPXWKJZIAA-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(C)=NC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 MZEXYPXWKJZIAA-UHFFFAOYSA-N 0.000 claims 1
- QWVGYCGJYBKYSC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(5-phenyl-1,3-oxazol-2-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC=4OC(=CN=4)C=4C=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 QWVGYCGJYBKYSC-UHFFFAOYSA-N 0.000 claims 1
- NHIUBSCZOIMDJS-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[(5-propan-2-yl-1,2,4-oxadiazol-3-yl)methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(C(C)C)=NC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 NHIUBSCZOIMDJS-UHFFFAOYSA-N 0.000 claims 1
- RJWYVPVVMDCLSE-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[1-(3-methylbutyl)pyrazol-4-yl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NN(CCC(C)C)C=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 RJWYVPVVMDCLSE-UHFFFAOYSA-N 0.000 claims 1
- BPFWZVHBOZPPJX-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[2-(1-hydroxycyclopentyl)ethynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OCC3OCCOC3)C=2)=O)CC2)C2=CC=1C#CC1(O)CCCC1 BPFWZVHBOZPPJX-UHFFFAOYSA-N 0.000 claims 1
- JZZYQXJKGTXYCE-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[2-(3-methylimidazol-4-yl)ethynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C=NC=C1C#CC1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 JZZYQXJKGTXYCE-UHFFFAOYSA-N 0.000 claims 1
- NIDXRAREIYMXAW-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[2-(4-methoxyphenyl)ethynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=CC(OC)=CC=C1C#CC1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 NIDXRAREIYMXAW-UHFFFAOYSA-N 0.000 claims 1
- MWUKVCCBFVEQTL-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-[6-(trifluoromethyl)pyridin-3-yl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 MWUKVCCBFVEQTL-UHFFFAOYSA-N 0.000 claims 1
- UDEWBHZYVLSYNN-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-ethynyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#C)C=C3CCN2C(=O)N=C1OCC1COCCO1 UDEWBHZYVLSYNN-UHFFFAOYSA-N 0.000 claims 1
- FYDLWSDXHIOKMI-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-hex-1-ynyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCCCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 FYDLWSDXHIOKMI-UHFFFAOYSA-N 0.000 claims 1
- KFLOTFVSWTXWOA-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-methoxy-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 KFLOTFVSWTXWOA-UHFFFAOYSA-N 0.000 claims 1
- UCKMDBYAIBGKDN-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-pyridin-3-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=NC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 UCKMDBYAIBGKDN-UHFFFAOYSA-N 0.000 claims 1
- RDXHLXPVIQVMJC-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-pyridin-4-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=CN=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 RDXHLXPVIQVMJC-UHFFFAOYSA-N 0.000 claims 1
- GBEMSGJRHUHGQM-UHFFFAOYSA-N 2-(1,4-dioxan-2-ylmethoxy)-9-pyrimidin-5-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4C=NC=NC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 GBEMSGJRHUHGQM-UHFFFAOYSA-N 0.000 claims 1
- YYMRQEAZLNSZOV-UHFFFAOYSA-N 2-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzonitrile Chemical compound C1=C2C3=CC=C(C=4C(=CC=CC=4)C#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 YYMRQEAZLNSZOV-UHFFFAOYSA-N 0.000 claims 1
- BSFKCPBKRKWLLO-UHFFFAOYSA-N 2-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]indole-1-carboxylic acid Chemical class O1C(COCC1)COC1=NC(N2C(C3=CC=C(C=C3CC2)C=2N(C3=CC=CC=C3C=2)C(=O)O)=C1)=O BSFKCPBKRKWLLO-UHFFFAOYSA-N 0.000 claims 1
- YYMRQEAZLNSZOV-LJQANCHMSA-N 2-[2-[[(2r)-1,4-dioxan-2-yl]methoxy]-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzonitrile Chemical compound C1=C2C3=CC=C(C=4C(=CC=CC=4)C#N)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 YYMRQEAZLNSZOV-LJQANCHMSA-N 0.000 claims 1
- YYMRQEAZLNSZOV-IBGZPJMESA-N 2-[2-[[(2s)-1,4-dioxan-2-yl]methoxy]-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzonitrile Chemical compound C1=C2C3=CC=C(C=4C(=CC=CC=4)C#N)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 YYMRQEAZLNSZOV-IBGZPJMESA-N 0.000 claims 1
- XTFGTMPOQSBSFP-GOSISDBHSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-(2-propoxyethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCOCCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@H]1COCCO1 XTFGTMPOQSBSFP-GOSISDBHSA-N 0.000 claims 1
- ZKHKSLQAUALGNN-QGZVFWFLSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-(3-methoxypropyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@H]1COCCO1 ZKHKSLQAUALGNN-QGZVFWFLSA-N 0.000 claims 1
- CLGGBTXQLRICFB-LJQANCHMSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-(oxan-4-yloxymethyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COC4CCOCC4)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 CLGGBTXQLRICFB-LJQANCHMSA-N 0.000 claims 1
- FXENJTMDNMCZIQ-LJQANCHMSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-[2-(1-hydroxycyclopentyl)ethyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OC[C@@H]3OCCOC3)C=2)=O)CC2)C2=CC=1CCC1(O)CCCC1 FXENJTMDNMCZIQ-LJQANCHMSA-N 0.000 claims 1
- LGDSFSUAFPMIIJ-LJQANCHMSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-[2-(4-hydroxyoxan-4-yl)ethynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OC[C@@H]3OCCOC3)C=2)=O)CC2)C2=CC=1C#CC1(O)CCOCC1 LGDSFSUAFPMIIJ-LJQANCHMSA-N 0.000 claims 1
- PXLDABOJDRUBRB-GOSISDBHSA-N 2-[[(2r)-1,4-dioxan-2-yl]methoxy]-9-pentyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@H]1COCCO1 PXLDABOJDRUBRB-GOSISDBHSA-N 0.000 claims 1
- PEFSAXPTEDRHFK-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-ethoxyethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCOCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 PEFSAXPTEDRHFK-KRWDZBQOSA-N 0.000 claims 1
- ALSNCWKOUFIJHW-ZYZRXSCRSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-ethylhexylamino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(NCC(CC)CCCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 ALSNCWKOUFIJHW-ZYZRXSCRSA-N 0.000 claims 1
- HDGSQKHLTYKQFN-HNNXBMFYSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-fluoroethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCF)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 HDGSQKHLTYKQFN-HNNXBMFYSA-N 0.000 claims 1
- VFPRXDIPJDALBQ-INIZCTEOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-methoxyethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 VFPRXDIPJDALBQ-INIZCTEOSA-N 0.000 claims 1
- WCHQRUYPBWMRFP-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-propan-2-yloxyethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCOC(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 WCHQRUYPBWMRFP-SFHVURJKSA-N 0.000 claims 1
- XTFGTMPOQSBSFP-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(2-propoxyethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCOCCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 XTFGTMPOQSBSFP-SFHVURJKSA-N 0.000 claims 1
- ZYKSMEXRFQZAAW-IBGZPJMESA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-ethyl-3-hydroxypentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(O)(CC)CC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 ZYKSMEXRFQZAAW-IBGZPJMESA-N 0.000 claims 1
- FUQAHVVPRZZLSA-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-hydroxy-3-methylbutyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(C)(O)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 FUQAHVVPRZZLSA-KRWDZBQOSA-N 0.000 claims 1
- LACCZGDYHGONEM-YMXDCFFPSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-hydroxy-4,4-dimethylpentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(O)C(C)(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 LACCZGDYHGONEM-YMXDCFFPSA-N 0.000 claims 1
- HXNYJZAEGHSVKR-YMXDCFFPSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-hydroxy-4-methylpentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(O)C(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 HXNYJZAEGHSVKR-YMXDCFFPSA-N 0.000 claims 1
- DPDKIIHUMBDOHL-JRZJBTRGSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-hydroxybutyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(O)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 DPDKIIHUMBDOHL-JRZJBTRGSA-N 0.000 claims 1
- ARXUTZULCOVLEU-ZVAWYAOSSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-hydroxypentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(O)CC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 ARXUTZULCOVLEU-ZVAWYAOSSA-N 0.000 claims 1
- FRYSOWASMQOUDH-YDNXMHBPSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-methoxy-4-methylpentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(OC)C(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 FRYSOWASMQOUDH-YDNXMHBPSA-N 0.000 claims 1
- ZKGGBGUHHLWFKC-PKHIMPSTSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-methoxybutyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCC(C)OC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 ZKGGBGUHHLWFKC-PKHIMPSTSA-N 0.000 claims 1
- ZKHKSLQAUALGNN-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-methoxypropyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 ZKHKSLQAUALGNN-KRWDZBQOSA-N 0.000 claims 1
- DOHKQKMAJBATQH-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(3-methylbut-1-ynyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 DOHKQKMAJBATQH-SFHVURJKSA-N 0.000 claims 1
- NSCFDDAIAZZOIZ-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(4-hydroxy-4-methylpentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCC(C)(O)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 NSCFDDAIAZZOIZ-SFHVURJKSA-N 0.000 claims 1
- VFYZBZNEAMFLHG-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(4-hydroxybutyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCCO)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 VFYZBZNEAMFLHG-KRWDZBQOSA-N 0.000 claims 1
- RUKXQQIDEBYETE-PKHIMPSTSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(4-hydroxypentyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCC(O)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 RUKXQQIDEBYETE-PKHIMPSTSA-N 0.000 claims 1
- KZBSTXQYMUCJLA-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(4-methoxybutyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(CCCCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 KZBSTXQYMUCJLA-SFHVURJKSA-N 0.000 claims 1
- FKTFVDHBAYCXFO-GGYWPGCISA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC4OCCCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 FKTFVDHBAYCXFO-GGYWPGCISA-N 0.000 claims 1
- NWHHOSIUJNIWBU-IBGZPJMESA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxan-4-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC4CCOCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 NWHHOSIUJNIWBU-IBGZPJMESA-N 0.000 claims 1
- FDBUJVHYUALRBC-FQEVSTJZSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxan-4-ylmethoxymethyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COCC4CCOCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 FDBUJVHYUALRBC-FQEVSTJZSA-N 0.000 claims 1
- VBMLIXPOHJZPOV-IBGZPJMESA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxan-4-ylmethylamino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(NCC4CCOCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 VBMLIXPOHJZPOV-IBGZPJMESA-N 0.000 claims 1
- SUTVBPGMNVGUEY-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxetan-3-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC4COC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 SUTVBPGMNVGUEY-KRWDZBQOSA-N 0.000 claims 1
- MJIQIOIDMFDDBI-KRWDZBQOSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-(oxetan-3-yloxymethyl)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COC4COC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 MJIQIOIDMFDDBI-KRWDZBQOSA-N 0.000 claims 1
- VHYAHDGHXLDCRL-SFHVURJKSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-[(3-methyloxetan-3-yl)methoxymethyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OC[C@H]3OCCOC3)C=2)=O)CC2)C2=CC=1COCC1(C)COC1 VHYAHDGHXLDCRL-SFHVURJKSA-N 0.000 claims 1
- FXENJTMDNMCZIQ-IBGZPJMESA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-[2-(1-hydroxycyclopentyl)ethyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OC[C@H]3OCCOC3)C=2)=O)CC2)C2=CC=1CCC1(O)CCCC1 FXENJTMDNMCZIQ-IBGZPJMESA-N 0.000 claims 1
- JYCHUBYLKOFCRG-FQEVSTJZSA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-[3-(2-ethoxyethoxy)prop-1-ynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCOCCOCC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 JYCHUBYLKOFCRG-FQEVSTJZSA-N 0.000 claims 1
- XVEMVXXDOOBYHB-IBGZPJMESA-N 2-[[(2s)-1,4-dioxan-2-yl]methoxy]-9-[3-(2-methoxyethoxy)prop-1-ynyl]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CCOCCOC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 XVEMVXXDOOBYHB-IBGZPJMESA-N 0.000 claims 1
- QPMSMEGRSPIYCY-UHFFFAOYSA-N 2-[[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]oxy]acetonitrile Chemical compound C1=C2C3=CC=C(OCC#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 QPMSMEGRSPIYCY-UHFFFAOYSA-N 0.000 claims 1
- ZOPUGIAXQNDWQJ-UHFFFAOYSA-N 3-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 ZOPUGIAXQNDWQJ-UHFFFAOYSA-N 0.000 claims 1
- XHQGJPXVKBSGHO-UHFFFAOYSA-N 3-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]-5-fluorobenzamide Chemical compound NC(=O)C1=CC(F)=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 XHQGJPXVKBSGHO-UHFFFAOYSA-N 0.000 claims 1
- YDRDGVRBICOWFX-UHFFFAOYSA-N 3-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 YDRDGVRBICOWFX-UHFFFAOYSA-N 0.000 claims 1
- KXXDHPDMCWWMPD-UHFFFAOYSA-N 3-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzonitrile Chemical compound C1=C2C3=CC=C(C=4C=C(C=CC=4)C#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 KXXDHPDMCWWMPD-UHFFFAOYSA-N 0.000 claims 1
- YHYPVCLQMAAXSH-UHFFFAOYSA-N 3-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]pyridine-4-carbonitrile Chemical compound C1=C2C3=CC=C(C=4C(=CC=NC=4)C#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 YHYPVCLQMAAXSH-UHFFFAOYSA-N 0.000 claims 1
- LGNHTQPLDMLJSM-UHFFFAOYSA-N 4-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 LGNHTQPLDMLJSM-UHFFFAOYSA-N 0.000 claims 1
- UCJBLOVGSXNIMZ-UHFFFAOYSA-N 4-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]benzonitrile Chemical compound C1=C2C3=CC=C(C=4C=CC(=CC=4)C#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 UCJBLOVGSXNIMZ-UHFFFAOYSA-N 0.000 claims 1
- MOTGLUMBOMRAEA-UHFFFAOYSA-N 4-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]pyridine-3-carbonitrile Chemical compound C1=C2C3=CC=C(C=4C(=CN=CC=4)C#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 MOTGLUMBOMRAEA-UHFFFAOYSA-N 0.000 claims 1
- KIMZPIYRCIUCII-UHFFFAOYSA-N 5-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]-2-fluorobenzamide Chemical compound C1=C(F)C(C(=O)N)=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 KIMZPIYRCIUCII-UHFFFAOYSA-N 0.000 claims 1
- SJZKKRQYCSSGHV-UHFFFAOYSA-N 5-[2-(1,4-dioxan-2-ylmethoxy)-4-oxo-6,7-dihydropyrimido[6,1-a]isoquinolin-9-yl]pent-4-ynenitrile Chemical compound C1=C2C3=CC=C(C#CCCC#N)C=C3CCN2C(=O)N=C1OCC1COCCO1 SJZKKRQYCSSGHV-UHFFFAOYSA-N 0.000 claims 1
- BGXQHNQYMRFIGL-SFHVURJKSA-N 9-(2,2-dimethylbutylamino)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(NCC(C)(C)CC)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 BGXQHNQYMRFIGL-SFHVURJKSA-N 0.000 claims 1
- URZPEGGUMAIOJZ-KRWDZBQOSA-N 9-(2,2-dimethylpropoxy)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCC(C)(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 URZPEGGUMAIOJZ-KRWDZBQOSA-N 0.000 claims 1
- DFIYXVFBAYHFHF-SFHVURJKSA-N 9-(2,2-dimethylpropoxymethyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(COCC(C)(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 DFIYXVFBAYHFHF-SFHVURJKSA-N 0.000 claims 1
- NVXCVOSFBURWAP-UHFFFAOYSA-N 9-(2,3-dimethoxyphenyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1OC NVXCVOSFBURWAP-UHFFFAOYSA-N 0.000 claims 1
- RYKVFDPZZFYMCH-UHFFFAOYSA-N 9-(2,5-dimethoxyphenyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC=C(OC)C(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 RYKVFDPZZFYMCH-UHFFFAOYSA-N 0.000 claims 1
- YWPOGCYNFZSDEW-UHFFFAOYSA-N 9-(2,6-dimethoxypyridin-3-yl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=NC(OC)=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 YWPOGCYNFZSDEW-UHFFFAOYSA-N 0.000 claims 1
- QKGNXXBOQFMEJH-UHFFFAOYSA-N 9-(2-chlorophenyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound ClC1=CC=CC=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 QKGNXXBOQFMEJH-UHFFFAOYSA-N 0.000 claims 1
- GOABXHRYGPVPPU-UHFFFAOYSA-N 9-(2-cyclohexylethynyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CCCCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 GOABXHRYGPVPPU-UHFFFAOYSA-N 0.000 claims 1
- IRWVHUUXYLAIAL-UHFFFAOYSA-N 9-(2-cyclopentylethynyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CCCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 IRWVHUUXYLAIAL-UHFFFAOYSA-N 0.000 claims 1
- CGLMQSKTQZSXCH-GOSISDBHSA-N 9-(2-cyclopropylethyl)-2-[[(2r)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(CCC4CC4)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 CGLMQSKTQZSXCH-GOSISDBHSA-N 0.000 claims 1
- CGLMQSKTQZSXCH-SFHVURJKSA-N 9-(2-cyclopropylethyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(CCC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 CGLMQSKTQZSXCH-SFHVURJKSA-N 0.000 claims 1
- IRBAWVGZNJIROV-UHFFFAOYSA-N 9-(2-cyclopropylethynyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 IRBAWVGZNJIROV-UHFFFAOYSA-N 0.000 claims 1
- IRBAWVGZNJIROV-GOSISDBHSA-N 9-(2-cyclopropylethynyl)-2-[[(2r)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 IRBAWVGZNJIROV-GOSISDBHSA-N 0.000 claims 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 claims 1
- XUUMONIOFNJCFP-UHFFFAOYSA-N 9-(3,3-dimethylbut-1-ynyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(C#CC(C)(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 XUUMONIOFNJCFP-UHFFFAOYSA-N 0.000 claims 1
- JYBKRGIWCQSOHN-UHFFFAOYSA-N 9-(3,5-dichlorophenyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound ClC1=CC(Cl)=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1 JYBKRGIWCQSOHN-UHFFFAOYSA-N 0.000 claims 1
- QYUIEQFTTNJTMS-UHFFFAOYSA-N 9-(3,5-dimethyl-1h-pyrazol-4-yl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CC1=NNC(C)=C1C1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 QYUIEQFTTNJTMS-UHFFFAOYSA-N 0.000 claims 1
- LMVWRWNWERGULV-UHFFFAOYSA-N 9-(3,6-dihydro-2h-pyran-4-yl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4CCOCC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 LMVWRWNWERGULV-UHFFFAOYSA-N 0.000 claims 1
- YHSONAVIPVCZDX-UHFFFAOYSA-N 9-(3-anilinoprop-1-ynyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CCNC=4C=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 YHSONAVIPVCZDX-UHFFFAOYSA-N 0.000 claims 1
- LCNCDLIVLWJDTQ-QFIPXVFZSA-N 9-(3-anilinopropyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(CCCNC=4C=CC=CC=4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 LCNCDLIVLWJDTQ-QFIPXVFZSA-N 0.000 claims 1
- GKJJFXZUNPOFRS-UHFFFAOYSA-N 9-(3-chloro-2-methoxypyridin-4-yl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=NC=CC(C=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=C1Cl GKJJFXZUNPOFRS-UHFFFAOYSA-N 0.000 claims 1
- YKKXXDAPUOFZDC-LJQANCHMSA-N 9-(3-cyclopropylpropoxy)-2-[[(2r)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCCCC4CC4)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 YKKXXDAPUOFZDC-LJQANCHMSA-N 0.000 claims 1
- YKKXXDAPUOFZDC-IBGZPJMESA-N 9-(3-cyclopropylpropoxy)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCCCC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 YKKXXDAPUOFZDC-IBGZPJMESA-N 0.000 claims 1
- BUJAVCYRADIVPH-IBGZPJMESA-N 9-(4,4-dimethylpentoxy)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OCCCC(C)(C)C)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OC[C@@H]1COCCO1 BUJAVCYRADIVPH-IBGZPJMESA-N 0.000 claims 1
- HVVOJEOEPSKBIY-UHFFFAOYSA-N 9-(cyclohexen-1-yl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C=4CCCCC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 HVVOJEOEPSKBIY-UHFFFAOYSA-N 0.000 claims 1
- NOKFUPIFXYMEMG-FQEVSTJZSA-N 9-(cyclohexylmethylamino)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(NCC4CCCCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 NOKFUPIFXYMEMG-FQEVSTJZSA-N 0.000 claims 1
- XIWIBKWGVWDVAZ-FQEVSTJZSA-N 9-(cyclohexyloxymethyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COC4CCCCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 XIWIBKWGVWDVAZ-FQEVSTJZSA-N 0.000 claims 1
- WKKMOSLPKTZYHE-FQEVSTJZSA-N 9-(cyclopentylmethoxymethyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COCC4CCCC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 WKKMOSLPKTZYHE-FQEVSTJZSA-N 0.000 claims 1
- YJRYAOMRRMQDAV-UHFFFAOYSA-N 9-(cyclopentyloxymethyl)-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COC4CCCC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 YJRYAOMRRMQDAV-UHFFFAOYSA-N 0.000 claims 1
- YJRYAOMRRMQDAV-LJQANCHMSA-N 9-(cyclopentyloxymethyl)-2-[[(2r)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COC4CCCC4)C=C3CCN2C(=O)N=C1OC[C@H]1COCCO1 YJRYAOMRRMQDAV-LJQANCHMSA-N 0.000 claims 1
- XFWPJCXTBXFACX-KRWDZBQOSA-N 9-(cyclopropylmethoxy)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 XFWPJCXTBXFACX-KRWDZBQOSA-N 0.000 claims 1
- ABVVTAOXKDJPMY-SFHVURJKSA-N 9-(cyclopropylmethoxymethyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(COCC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 ABVVTAOXKDJPMY-SFHVURJKSA-N 0.000 claims 1
- LDEXEZSXQFUIEE-UHFFFAOYSA-N 9-[(1,5-dimethylpyrazol-3-yl)methoxy]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C(C)=CC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 LDEXEZSXQFUIEE-UHFFFAOYSA-N 0.000 claims 1
- UWACCCXIIBRQDS-UHFFFAOYSA-N 9-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methoxy]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(OCC=4N=C(ON=4)C4CC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 UWACCCXIIBRQDS-UHFFFAOYSA-N 0.000 claims 1
- WVXXBOGIESBOAV-UHFFFAOYSA-N 9-[(5-tert-butyl-1,2,4-oxadiazol-3-yl)methoxy]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(C(C)(C)C)=NC(COC=2C=C3C(C=4N(C(N=C(OCC5OCCOC5)C=4)=O)CC3)=CC=2)=N1 WVXXBOGIESBOAV-UHFFFAOYSA-N 0.000 claims 1
- SVTUOYWRUDSQLS-UHFFFAOYSA-N 9-[(5-tert-butyl-1,3-oxazol-2-yl)methoxy]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound O1C(C(C)(C)C)=CN=C1COC1=CC=C2C3=CC(OCC4OCCOC4)=NC(=O)N3CCC2=C1 SVTUOYWRUDSQLS-UHFFFAOYSA-N 0.000 claims 1
- RNGJWXRTLWVRTL-UHFFFAOYSA-N 9-[3-(benzylamino)prop-1-ynyl]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CCNCC=4C=CC=CC=4)C=C3CCN2C(=O)N=C1OCC1COCCO1 RNGJWXRTLWVRTL-UHFFFAOYSA-N 0.000 claims 1
- OQPXEVMRXYMSCF-UHFFFAOYSA-N 9-[3-[benzyl(methyl)amino]prop-1-ynyl]-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=CC=CC=1CN(C)CC#CC(C=1)=CC=C2C=1CCN(C(N=1)=O)C2=CC=1OCC1COCCO1 OQPXEVMRXYMSCF-UHFFFAOYSA-N 0.000 claims 1
- DJFFTHUKYSGWTP-FQEVSTJZSA-N 9-[cyclohexyl(methyl)amino]-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C=C(C=2N(C(N=C(OC[C@H]3OCCOC3)C=2)=O)CC2)C2=CC=1N(C)C1CCCCC1 DJFFTHUKYSGWTP-FQEVSTJZSA-N 0.000 claims 1
- ZSYGTUKDHOKEBC-UHFFFAOYSA-N 9-cyclopropyl-2-(1,4-dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C4CC4)C=C3CCN2C(=O)N=C1OCC1COCCO1 ZSYGTUKDHOKEBC-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Spoj prema Formuli Ia:
[image]
pri čemu
R1 je H, Me, ili halo;
L1 je odsutno ili je -O-, -S-, ili -NR4a-;
G je
R2,
-W-L2-R2, ili
-W-L3-R3;
W je C1-4 alkilen, C2-4 alkenilen koji ima jednu dvostruku vezu, ili C2-4 alkinilen koji ima jednu trostruku vezu;
L2 je odsutno ili je -O-;
R2 je
- H,
- C1-8 alkil, po izboru supstituiran sa jednom do tri grupe nezavisno odabrane od
∘ OH,
∘ halo,
∘ CN,
∘ C1-6 alkoksi,
∘ C3-7 cikloalkila,
∘ 4-6 -članog heterocikloalkila koji sadrži jedan do tri heteroatoma nezavisno odabrana od S, i O,
∘ 5-6 -članog heteroarila koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O, i
∘ fenila,
- C4-7 cikloalkenil koji sadrži jednu dvostruku vezu,
- 5-7 -člani heterocikloalkenil koji sadrži jednu dvostruku vezu, i jedan do tri heteroatoma nezavisno odabrana od N, O, i S,
- C3-7 cikloalkil po izboru supstituiran sa jednom ili više nezavisno odabranih R5 grupa,
- 4-10 -člani heterocikloalkil koji sadrži jedan do dva heteroatoma nezavisno odabrana od S, i O, po izboru supstituiran sa jednom do tri nezavisno odabrane R5 grupe,
- 5-10 -člani heteroaril koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O po izboru supstituiran sa jednom do tri nezavisno odabrane R6 grupe, ili
- C6-10 aril po izboru supstituiran sa jednom ili više nezavisno odabranih R6 grupa;
L3 je -NR4b-;
R3 je
- C1-4 alkil supstituiran sa
∘ C6-10 arilom po izboru supstituiranim sa jednom ili više nezavisno odabranih R7 grupa, ili
∘ 5-10 -članim heteroarilom koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O, po izboru supstituiranim sa jednom ili više R nezavisno odabranih R7 grupa,
- 5-10 -člani heteroaril koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O, po izboru supstituiran sa jednom ili više nezavisno odabranih R7 grupa, ili
- C6-10 aril po izboru supstituiran sa jednom ili više nezavisno odabranih R7 grupa;
Svako R4a i R4b je nezavisno odabrano od H, C1-4 alkila, i C3-7 cikloalkila;
R5 je okso ili R6;
R6 je
- OH,
- halo,
- -NO2,
- C1-6 alkil po izboru supstituiran sa jednom do tri grupe nezavisno odabrane od halo, i OH,
- C1-6 alkoksi po izboru supstituiran sa jednom do tri grupe nezavisno odabrane od halo, i OH,
- C3-7 cikloalkil,
- -C(=O)OR8,
- -C(=O)NR9R10,
- -NHC(=O)-C1-4 alkil,
- -CN,
- fenil,
- -O-fenil,
- 4-7 -člani heterocikloalkil koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, O, i S, ili
- 5-6 -člani heteroaril koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, O, i S, po izboru supstituiran sa jednim ili više nezavisno odabranih C1-4 alkila, C1-4 alkoksi, CN, halo, i -C(=O)OR11;
R7 je C1-4 alkil, ili halo; i
svako od R8, R9, R10 i R11 je nezavisno odabrano od H i C1-4 alkila,
ili farmaceutski prihvatljiva sol, ili solvat, ili solvat farmaceutski prihvatljive soli, za primjenu u liječenju multiple skleroze.
2. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 1, pri čemu R1 je H.
3. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 1, pri čemu spoj je u skladu sa Formulom IIa ili IIIa:
[image]
ili
[image]
pri čemu L1, W, L2, i R2 su kao što su opisani u patentnom zahtjevu 1.
4. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 3, pri čemu spoj je u skladu sa Formulom IIa, i L1 je odsutno.
5. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 3, pri čemu spoj je u skladu sa Formulom IIIa, i L1 je odsutno ili je -O-; W je C1-4 alkilen, ili C2-4 alkenilen koji ima jednu dvostruku vezu.
6. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 3, pri čemu spoj je u skladu sa Formulom IIIa, i L1 je odsutno; W je C2-4 alkinilen koji ima jednu trostruku vezu; i L2, i R2 su kao što su opisani u patentnom zahtjevu 1.
7. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 5 ili 6, pri čemu L2 je odsutno.
8. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 3, pri čemu spoj je u skladu sa Formulom IIIa, pri čemu L1 i L2 su odsutni, W je -CH2-CH2-, -CH=CH-, ili -C≡C-, i R2 je kao što je opisano u patentnom zahtjevu 1.
9. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema bilo kojem od patentnih zahtjeva 3-8, pri čemu R2 je 5-10 -člani heteroaril koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O, po izboru supstituiran sa jednom do tri nezavisno odabrane R6 grupe.
10. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 9, pri čemu R6 je odabrano od OH, halo, C1-6 alkila, C1-6 alkila supstituiranog sa jednim ili više halo, C1-6 alkoksi, -CN, C3-7 cikloalkila, 4-7 -članog heterocikloalkila koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, O, i S, i fenila.
11. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema bilo kojem od patentnih zahtjeva 3-8 pri čemu R2 je C1-8 alkil po izboru supstituiran sa jednom do tri grupe nezavisno odabrane od OH, halo, CN, C1-6 alkoksi, C3-7 cikloalkila, 4-6 -članog heterocikloalkila koji sadrži jedan do tri heteroatoma nezavisno odabrana od S, i O, 5-6 -članog heteroarila koji sadrži jedan do tri heteroatoma nezavisno odabrana od N, S, i O, i fenila
12. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema bilo kojem od patentnih zahtjeva 3-8, pri čemu R2 je C3-7 cikloalkil.
13. Spoj ili farmaceutski prihvatljiva sol istog za primjenu u liječenju multiple skleroze, prema patentnom zahtjevu 1, pri čemu spoj je odabrano od:
9-Aliloksi-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-piridin-3-il-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-piridin-4-il-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzonitrila,
3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzonitrila,
4-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzonitrila,
[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-iloksi]-acetonitrila,
2-([1,4]Dioksan-2-ilmetoksi)-9-(oksazol-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(piridin-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(3,5-Dikloro-fenil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Benzofuran-2-il-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
terc-butil estera 2-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-indol-1-karboksilne kiseline,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1H-indol-2-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-metoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-trifluorometil-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metil-3H-imidazol-4-iletinil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(5-terc-Butil-[1,2,4]oksadiazol-3-ilmetoksi)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
Metilamida 5-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-piridin-2-karboksilne kiseline,
2-([1,4]Dioksan-2-ilmetoksi)-9-pent-1-inil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-piridin-2-il-etil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-pirazin-2-il-etil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1H-indol-5-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-metoksi-fenil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-metoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1H-indazol-5-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(4-metoksi-fenil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzamida,
5-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-2-fluoro-benzamida,
N-{3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-fenil}-acetamida,
9-Ciklopropiletinil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1-hidroksi-ciklopentiletinil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-pirimidin-5-il-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Cikloheks-1-enil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1-metil-1H-indol-5-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-metil-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-piridin-2-iletinil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-prop-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
5-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-pent-4-innitrila,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-prop-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(4-metoksi-feniletinil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-piridin-3-iletinil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
4-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-N-metil-benzamida,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-fenil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2-kloro-fenil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(4-hidroksi-but-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(1,5-Dimetil-1H-pirazol-3-ilmetoksi)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1-metil-1H-pirazol-3-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metil-[1,2,4]oksadiazol-5-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(4-morfolin-4-il-fenil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-4-fluoro-benzamida,
3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-5-fluoro-benzamida,
9-(3,3-Dimetil-but-1-inil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-piridin-4-iletinil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metil-izoksazol-5-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-3-metil-but-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-metoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(3,6-Dihidro-2H-piran-4-il)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
5-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-piridin-2-karbonitrila,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-izopropoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-etoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-morfolin-4-il-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2,3-Dimetoksi-fenil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(3-kloro-2-metoksi-piridin-4-il)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-metil-piridin-4-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
3-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-izonikotinonitrila,
9-(2,5-Dimetoksi-fenil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-etoksi-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2,6-Dimetoksi-piridin-3-il)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
4-[2-([1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-nikotinonitrila,
9-terc-Butoksimetil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(2-pirolidin-1-il-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(6-pirolidin-1-il-piridin-3-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-fenil-oksazol-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(5-terc-Butil-oksazol-2-ilmetoksi)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(5-Ciklopropil-[1,2,4]oksadiazol-3-ilmetoksi)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-etil-[1,2,4]oksadiazol-3-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-metil-[1,2,4]oksadiazol-3-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-izopropil-[1,2,4]oksadiazol-3-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopentiletinil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Cikloheksiletinil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metil-but-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-heks-1-inil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-[3-(Benzil-metil-amino)-prop-1-inil]-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-5-metil-heks-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-but-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopropil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-pent-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-4-metil-pent-1-inil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-etil-3-hidroksi-pent-1-inil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-3-fenil-but-1-inil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-(3-Benzilamino-prop-1-inil)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-[(furan-2-ilmetil)-amino]-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1-etil-1H-pirazol-4-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-[1-(3-metil-butil)-1H-pirazol-4-il]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(5-metil-furan-2-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-heks-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(3,5-Dimetil-1H-pirazol-4-il)-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1H-pirazol-4-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(1-propil-1H-pirazol-4-il)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-[2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzonitrila,
2-[2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-4-okso-6,7-dihidro-4H-pirimido[6,1-a]izohinolin-9-il]-benzonitrila,
9-(5-Ciklopropil-[1,2,4]oksadiazol-3-ilmetoksi)-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolm-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-etinil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-pirimidin-2-iletinil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-fenilamino-prop-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-3-piridin-3-il-prop-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopentiloksimetil-2-([1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-4-metil-pent-1-inil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-Ciklopropiletinil-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metil-but-1-inil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-imidazol-1-il-prop-1-inil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-(2-Ciklopropil-etil)-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopentiloksimetil-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-3-piridin-3-il-propil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Aliloksi-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Aliloksi-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-(tetrahidro-piran-4-iloksimetil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-{3-[(piridin-3-ilmetil)-amino]-prop-1-inil}-6,7-dihidro-pirimido[6,1-a]izohinolm-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-pentil-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona, 9-Ciklopropiletinil-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2-Ciklopropil-etil)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(oksetan-3-iloksimetil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metil-oksetan-3-ilmetoksimetil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2,2-Dimetil-butilamino)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-4-metil-pentil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-etil-heksilamino)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-metoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-etoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopropilmetoksi-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-fluoro-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-[3-(2-metoksi-etoksi)-prop-1-inil]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-[3-(2-etoksi-etoksi)-prop-1-inil]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-[3-(2-fluoro-etoksi)-prop-1-inil]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-(2,2-Dimetil-propoksimetil)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-Cikloheksiloksimetil-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-Ciklopropilmetoksimetil-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(tetrahidro-piran-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-butil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(4,4-Dimetil-pentiloksi)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-4-metil-pentil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-(3-Ciklopropil-propoksi)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-Cikloheksilamino-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-4,4-dimetil-pentil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-Ciklopentilmetoksimetil-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-butil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-fenilamino-propil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(4-hidroksi-pentil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(4-hidroksi-butil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(Cikloheksil-metil-amino)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
9-(Cikloheksilmetil-amino)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-[(tetrahidro-piran-4-ilmetil)-amino]-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-etil-3-hidroksi-pentil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-3-metil-butil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-hidroksi-pentil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(2,2-Dimetil-propoksi)-2-((S)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(tetrahidro-piran-4-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(4-hidroksi-4-metil-pentil)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(tetrahidro-piran-4-ilmetoksimetil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-([1,4]Dioksan-2-ilmetoksi)-9-metoksi-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(oksetan-3-ilmetoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
9-(3-Ciklopropil-propoksi)-2-((R)-1-[1,4]dioksan-2-ilmetoksi)-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-propil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-[2-(1-hidroksi-ciklopentil)-etil]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-(4-hidroksi-tetrahidro-piran-4-iletinil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-(3-metoksi-propil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-[2-(1-hidroksi-ciklopentil)-etil]-6,7-dihidro-pirimido[6,1-a] izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-propoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-izopropoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-propoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona,
2-((R)-1-[1,4]Dioksan-2-ilmetoksi)-9-(2-izopropoksi-etoksi)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona, i
2-((S)-1-[1,4]Dioksan-2-ilmetoksi)-9-(4-metoksi-butil)-6,7-dihidro-pirimido[6,1-a]izohinolin-4-ona.
14. Farmaceutska kompozicija za primjenu u liječenju multiple skleroze koja sadrži spoj ili farmaceutski prihvatljivu sol istog, prema bilo kojem od patentnih zahtjeva 1-13, i farmaceutski prihvatljiv nosač.
15. Farmaceutska kompozicija za primjenu u liječenju multiple skleroze prema patentnom zahtjevu 14 koja sadrži dodatni terapijski agens.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161578979P | 2011-12-22 | 2011-12-22 | |
EP17184834.4A EP3378862B1 (en) | 2011-12-22 | 2012-12-20 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220456T1 true HRP20220456T1 (hr) | 2022-05-27 |
Family
ID=47520068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220456TT HRP20220456T1 (hr) | 2011-12-22 | 2012-12-20 | Dihidropirimidinoizohinolinoni i njihove farmaceutske kompozicije za liječenje multiple skleroze |
HRP20171404TT HRP20171404T1 (hr) | 2011-12-22 | 2017-09-18 | Novi dihidropirimidinoizokinolinoni i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171404TT HRP20171404T1 (hr) | 2011-12-22 | 2017-09-18 | Novi dihidropirimidinoizokinolinoni i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja |
Country Status (35)
Country | Link |
---|---|
US (5) | US8927543B2 (hr) |
EP (3) | EP2794604B1 (hr) |
JP (1) | JP6062453B2 (hr) |
KR (1) | KR102012268B1 (hr) |
CN (1) | CN103998448B (hr) |
AR (1) | AR089284A1 (hr) |
AU (1) | AU2012357067B2 (hr) |
BR (1) | BR112014015142B1 (hr) |
CA (1) | CA2859578C (hr) |
CL (1) | CL2014001664A1 (hr) |
CO (1) | CO7010835A2 (hr) |
CR (1) | CR20140305A (hr) |
CY (1) | CY1119434T1 (hr) |
DK (2) | DK2794604T3 (hr) |
EA (1) | EA023826B1 (hr) |
ES (2) | ES2911449T3 (hr) |
HK (1) | HK1201528A1 (hr) |
HR (2) | HRP20220456T1 (hr) |
HU (1) | HUE12812237T4 (hr) |
IL (2) | IL233212B (hr) |
IN (1) | IN2014MN01033A (hr) |
LT (2) | LT2794604T (hr) |
MX (1) | MX351681B (hr) |
NI (1) | NI201400060A (hr) |
PE (1) | PE20141685A1 (hr) |
PH (1) | PH12014501178A1 (hr) |
PL (2) | PL3378862T3 (hr) |
PT (2) | PT3378862T (hr) |
SG (1) | SG11201403169PA (hr) |
SI (2) | SI2794604T1 (hr) |
TW (1) | TWI567073B (hr) |
UA (1) | UA111767C2 (hr) |
UY (1) | UY34545A (hr) |
WO (1) | WO2013092791A1 (hr) |
ZA (1) | ZA201404607B (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2794627T (pt) | 2011-12-22 | 2018-12-19 | Janssen Biopharma Inc | Nucleósidos substituídos, nucleótidos e análogos dos mesmos |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP2935262B1 (en) * | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
GB201319677D0 (en) * | 2013-11-07 | 2013-12-25 | Eth Z Rich | Cyclopropanation |
GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
KR102305710B1 (ko) * | 2017-03-06 | 2021-09-30 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Gpr84 수용체 길항제 및 이의 용도 |
EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
CA3082742A1 (en) * | 2017-11-15 | 2019-05-23 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |
PE20221786A1 (es) | 2019-12-19 | 2022-11-22 | Bayer Ag | Derivados de furoindazol |
WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
US20230405007A1 (en) | 2020-11-24 | 2023-12-21 | Galapagos Nv | Compound for use in and methods of treatment of fibrotic diseases |
CA3211437A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
EP4330260A1 (en) | 2021-04-29 | 2024-03-06 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
EP4355743A1 (en) | 2021-06-18 | 2024-04-24 | University of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
CN115572293A (zh) * | 2021-06-21 | 2023-01-06 | 武汉人福创新药物研发中心有限公司 | 用于gpr84拮抗剂的三环化合物 |
CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
JP2001509483A (ja) * | 1997-07-12 | 2001-07-24 | カンサー リサーチ キャンペーン テクノロジー リミテッド | サイクリン依存性キナーゼ阻害性プリン誘導体 |
CN1348452A (zh) * | 1999-03-31 | 2002-05-08 | 韦尔纳利斯有限公司 | 嘧啶并[6,1-a]异喹啉-4-酮的衍生物 |
US7501512B2 (en) * | 2003-07-08 | 2009-03-10 | Smithkline Beecham Corporation | Chemical compounds |
WO2005050225A2 (en) | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
AU2006284926A1 (en) * | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
EP2318377B1 (en) | 2008-07-31 | 2013-08-21 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
PT2794600T (pt) | 2011-12-22 | 2018-03-13 | Novartis Ag | Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide |
ES2630309T3 (es) | 2011-12-22 | 2017-08-21 | Connexios Life Sciences Pvt. Ltd. | Derivados de amigos cíclicos como inhibidores de la 11-beta-hidroxisteroide deshidrogenasa y usos de los mismos |
NZ626744A (en) | 2011-12-22 | 2016-05-27 | Connexios Life Sciences Pvt Ltd | Derivatives of aza adamantane and uses thereof |
EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
-
2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en not_active Ceased
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh active
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en active Pending
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko active IP Right Grant
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh active Active
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja active Active
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en active Application Filing
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt active IP Right Grant
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
-
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178A1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
-
2015
- 2015-03-02 HK HK15102096.2A patent/HK1201528A1/xx unknown
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
-
2017
- 2017-09-18 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
-
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
-
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220456T1 (hr) | Dihidropirimidinoizohinolinoni i njihove farmaceutske kompozicije za liječenje multiple skleroze | |
HRP20230209T1 (hr) | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina | |
HRP20210669T1 (hr) | Režim doziranja povezan s injektibilnim dugodjelujućim paliperidon esterima | |
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
IL264709B2 (en) | Pharmaceutical preparations containing a modified polycyclic pyridone derivative and a hemane prodrug | |
JP2011116788A5 (hr) | ||
HRP20221536T1 (hr) | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina | |
JP2018528229A5 (hr) | ||
HRP20150096T1 (hr) | 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi | |
HRP20140051T1 (hr) | Farmaceutski pripravci koji sadrže imidazokinolin(amine) i njihovi derivati prikladni za lokalno davanje | |
JP2011503057A5 (hr) | ||
WO2019132006A1 (ja) | コーテッドサンド及びその製造方法並びに鋳型の製造方法 | |
JP2015524450A5 (hr) | ||
RU2015143430A (ru) | Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств | |
JP2016525146A5 (hr) | ||
ES2174462T3 (es) | Formulacion autoestimulante para compuestos lipofilos. | |
RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
JP2014518884A5 (hr) | ||
NZ734905A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
JP2010540617A5 (hr) | ||
AR085602A1 (es) | Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes | |
RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
HRP20230215T1 (hr) | Supstituirani policiklički derivati piridona i njihov predlijek | |
AR082271A1 (es) | Composicion acuosa de ingrediente activo | |
JP2014516033A5 (hr) |